Bionano Genomics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2026 Annual Meeting of Stockholders held by Bionano Genomics, Inc. on May 14, 2026. The record date for the meeting was March 19, 2026, with 11,091,615 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
A total of 4,225,995 shares were present at the meeting, representing approximately 38.1% of outstanding shares. The following matters were voted upon:
- Proposal 1 (Election of Directors): Stockholders elected Albert Luderer, Ph.D., and Kristiina Vuori, M.D., Ph.D., as Class II Directors to serve until the 2029 Annual Meeting.
- Albert Luderer: 847,601 votes for; 143,790 votes withheld.
- Kristiina Vuori: 867,474 votes for; 123,917 votes withheld.
- Proposal 2 (Executive Compensation): Stockholders approved, on an advisory basis, the compensation of Named Executive Officers.
- 697,999 votes for; 216,553 votes against; 76,839 abstentions.
- Proposal 3 (Auditor Ratification): Stockholders ratified the selection of BDO USA, P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- 3,770,715 votes for; 206,541 votes against; 248,739 abstentions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Attendance at the Annual Meeting was approximately 38.1% of outstanding shares.
- Broker non-votes totaled 3,234,604 shares for the director election and executive compensation proposals.
- Albert A. Luderer, Ph.D., signed the report in his capacity as Interim Chief Executive Officer.
- BDO USA, P.C. has been ratified as the auditor for the fiscal year ending December 31, 2026.